cantharidin has been researched along with erlotinib hydrochloride in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gong, FR; Li, W; Liu, ZY; Shen, M; Tao, M; Wang, WJ; Wu, MY; Zhi, Q | 1 |
| He, M; Ji, XL | 1 |
2 other study(ies) available for cantharidin and erlotinib hydrochloride
| Article | Year |
|---|---|
Cantharidin and norcantharidin impair stemness of pancreatic cancer cells by repressing the β-catenin pathway and strengthen the cytotoxicity of gemcitabine and erlotinib.
Topics: Apoptosis; beta Catenin; Bridged Bicyclo Compounds, Heterocyclic; Cantharidin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Neoplastic Stem Cells; Pancreatic Neoplasms; Phosphorylation; Signal Transduction | 2015 |
Sodium cantharidate targets STAT3 and abrogates EGFR inhibitor resistance in osteosarcoma.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Cantharidin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Child; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mice; Mice, Nude; Osteosarcoma; Phosphorylation; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2019 |